SurgePays Stock Forecast, Price & News

SurgePays (NASDAQ:SURG) Frequently Asked Questions

Is SurgePays a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurgePays in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SurgePays stock.
View analyst ratings for SurgePays or view top-rated stocks.

How has SurgePays' stock been impacted by Coronavirus (COVID-19)?

SurgePays' stock was trading at $0.2965 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SURG stock has increased by 861.2% and is now trading at $2.85.
View which stocks have been most impacted by COVID-19.

Are investors shorting SurgePays?

SurgePays saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 352,600 shares, an increase of 67.9% from the December 31st total of 210,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 0.3 days. Currently, 3.2% of the company's shares are sold short.
View SurgePays' Short Interest.

When is SurgePays' next earnings date?

SurgePays is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for SurgePays.

How were SurgePays' earnings last quarter?

SurgePays, Inc. (NASDAQ:SURG) announced its earnings results on Tuesday, November, 16th. The medical equipment provider reported ($0.51) earnings per share for the quarter. The medical equipment provider earned $14.54 million during the quarter.
View SurgePays' earnings history.

What price target have analysts set for SURG?

1 brokerages have issued 1 year target prices for SurgePays' stock. Their forecasts range from $7.00 to $7.00. On average, they expect SurgePays' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 145.6% from the stock's current price.
View analysts' price targets for SurgePays or view top-rated stocks among Wall Street analysts.

Who are SurgePays' key executives?

SurgePays' management team includes the following people:

• Kevin Brian Cox, Chairman & Chief Executive Officer
• Anthony P. Nuzzo, President, Chief Operating Officer & Director
• Anthony G. Evers, Chief Financial Officer
• John Mott, Chief Technology Officer (LinkedIn Profile)
• David C. Ansani, Secretary, CAO & Chief Legal Counsel

Who are some of SurgePays' key competitors?

Some companies that are related to SurgePays include Fluent (FLNT), Travelzoo (TZOO), IZEA Worldwide (IZEA), Inuvo (INUV), theglobe.com (TGLO), IDW Media (IDW), Insignia Systems (ISIG), IDW Media (IDWM), China Yanyuan Yuhui Natl Ed Group (YYYH), Mobiquity Technologies (MOBQ), Oliveda International (OLVI), Mobiquity Technologies (MOBQD), CMG Holdings Group (CMGO), Mastermind (MMND) and Adaptive Medias (ADTM).
View all of SURG's competitors.

What other stocks do shareholders of SurgePays own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SurgePays investors own include Agilent Technologies (A), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Celldex Therapeutics (CLDX), Genocea Biosciences (GNCA), GTX (GTXI), Idera Pharmaceuticals (IDRA), Microbot Medical (MBOT), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL).

What is SurgePays' stock symbol?

SurgePays trades on the NASDAQ under the ticker symbol "SURG."

Who are SurgePays' major shareholders?

SurgePays' stock is owned by a variety of retail and institutional investors. Top institutional investors include Kestra Advisory Services LLC (0.41%). Company insiders that own SurgePays stock include David Allen May, John Mott and Kevin Brian Cox.
View institutional ownership trends for SurgePays.

Which major investors are buying SurgePays stock?

SURG stock was bought by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC. Company insiders that have bought SurgePays stock in the last two years include David Allen May, John Mott, and Kevin Brian Cox.
View insider buying and selling activity for SurgePays or or view top insider-buying stocks.

How do I buy shares of SurgePays?

Shares of SURG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SurgePays' stock price today?

One share of SURG stock can currently be purchased for approximately $2.85.

How much money does SurgePays make?

SurgePays has a market capitalization of $34.33 million and generates $54.41 million in revenue each year.

How many employees does SurgePays have?

SurgePays employs 31 workers across the globe.

What is SurgePays' official website?

The official website for SurgePays is www.surgeholdings.com.

Where are SurgePays' headquarters?

SurgePays is headquartered at 3845 Corporate Centre Dr, O'FALLON, MO 63368-8678, United States.

How can I contact SurgePays?

SurgePays' mailing address is 3845 Corporate Centre Dr, O'FALLON, MO 63368-8678, United States. The medical equipment provider can be reached via phone at (901) 302-9587 or via email at [email protected].